Evidence map›Paper›PMID 10809953›Full record

ReviewImmunology2000

The role of complement in the acquired immune response.

C H Nielsen, E M Fischer, R G Leslie

Open access · greenAbstract readReview
In one paragraph

Review in Immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Immunoglobulin M-degrading enzyme ofFrontiers in immunology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Venom fromJournal of immunology research · 2018
    Article
  13. Production of complement components by cells of the immune system.Clinical and experimental immunology · 2017
    Review
  14. Complement activation in progressive renal disease.World journal of nephrology · 2015
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

C H NielsenDepartment of Immunology and Microbiology, University of Southern Denmark, Odense, Denmark.
E M Fischer
R G Leslie
Hôpital Broussais · FRInserm · FRUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies over the past three decades have clearly established a central role for complement in the promotion of a humoral immune response. The primary function of complement, in this regard, is to opsonize antigen or immune complexes for uptake by complement receptor type 2 (CR2, CD21) expressed on B cells, follicular dendritic cells (FDC) and some T cells. A variety of mechanisms appear to be involved in complement-mediated promotion of the humoral response. These include: enhancement of antigen (Ag) uptake and processing by both Ag-specific and non-specific B cells for presentation to specific T cells; the activation of a CD21/CD19 complex-mediated signalling pathway in B cells, which provides a stimulus synergistic to that induced by antigen interaction with the B-cell receptor (BCR); and promotion of the interaction between B cells and FDC, where C3d-bearing immune complexes participate in intercellular bridging. Finally, current studies suggest that CR2 may also play a role in the determination of B-cell tolerance towards self-antigens and thereby hold the key to the previously observed correlation between deficiencies of the early complement components and autoimmune disease.

Indexed as

Antibody FormationAntigen PresentationB-LymphocytesComplement System ProteinsDendritic Cells, FollicularHumansImmune ToleranceLymphocyte ActivationComplement System Proteins

Identifiers

PMID10809953
PMCPMC2326995
OpenAlexW1973389156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.